A randomized, double blind, placebo-controlled, three arm, parallel group, multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of abetimus sodium in systemic lupus erythematosus (sle) patients with a history of renal disease.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Abetimus (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 03 Oct 2013 Status changed from recruiting to discontinued as reported by Sri Lanka Clinical Trials Registry.
- 17 Sep 2011 New trial record